Minneapolis A new study published in this month's European Journal of Nutrition demonstrates a strong correlation between reducing bone loss in non-obese postmenopausal women and the dose-dependent effect of soy germ isoflavones, particularly SoyLife. These findings support previous scientific findings regarding soy isoflavones for post-menopausal women.
According to the authors of the study, "Osteoporosis is a health condition experienced by about one in three postmenopausal women, with estrogen deficiency often acting as the major cause. Hormone replacement therapy has been the most effective treatment for maintaining bone density. This treatment often has adverse side effects such as an increased risk for endometrial cancer and breast cancer."
"It is imperative to find natural, safe and effective alternatives for women to help maintain bone health after menopause without the risky side effects associated with long-term hormone replacement therapy use. This promising research is another step in advancing soy germ isoflavones as a safe, effective option," said Jocelyn Mathern, RD and Technical Specialist, Acatris.
The study aimed to examine the effects of a high-dose supplementation of soy germ isoflavones (84 and 126 mg SoyLife EXTRA/day) in slowing bone loss in 90 early postmenopausal Chinese women. Isoflavones are found predominately in soy products. Their structure and functions are similar to estrogen, and observational studies suggest that higher intakes of soy and soy products may lower the prevalence of osteoporosis.
Soy isoflavones have been supported by proprietary scientific studies to promote women's health, bone health, heart health, prostate health and cognitive function. A focus of the study, SoyLife is a range of ingredients from soy germ, rich in isoflavones. More than just an isoflavone concentrate, SoyLife offers the complete spectrum of natural soy compounds, the Soy Matrix
Contact: Nicole Tronolone